...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >The dopamine D3/D2 Agonist (+)-PD-128,907 ((R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin -9-ol)) protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
【24h】

The dopamine D3/D2 Agonist (+)-PD-128,907 ((R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin -9-ol)) protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.

机译:多巴胺D3 / D2激动剂(+)-PD-128,907((R-(+)-反式-3,4a,10b-四氢-4-丙基-2H,5H-(1)苯并吡喃(4,3-b) -1,4-oxazin -9-ol))可预防小鼠的急性和可卡因性癫痫发作:D3受体参与的进一步证据。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Previous findings have demonstrated a protective role for dopamine D(3)/D(2) receptor agonists in the convulsant and lethal effects of acutely administered cocaine. Data are provided here to establish that the protection occurs through a D(3)-linked mechanism and that protection is extended to seizure kindling. The D(3) antagonist SB-277011-A [4-quinolinecarboxamide,N-[trans-4-[2-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)et hyl]-cyclohexyl]-(9CI)] prevented the anticonvulsant effect of the D(3)/D(2) receptor agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin -9-ol)] on cocaine-induced seizures. The protection afforded by the D(3)/D(2) agonist, (+)-PD-128,907, was eliminated in D(3) receptor-deficient mice. In D(2) receptor knockout mice, the anticonvulsant effects of (+)-PD-128,907 were preserved. (+)-PD-128,907 also prevented the acquisition and expression of cocaine-kindled seizures engendered by repeated daily dosing with 60 mg/kg cocaine. (+)-PD-128,907 also blocked the seizures induced in mice fully seizure kindled to cocaine. Although repeated dosing with cocaine increased the potency of cocaine to produce seizures and lethality (decreased ED(50) values), daily coadministration of (+)-PD-128,907 significantly prevented this potency shift. In mice treated daily with cocaine and (+)-PD-128,907, the density, but not the affinity, of D(3) receptors was increased. The specificity with which (+)-PD-128,907 acts upon this cocaine-driven process was demonstrated by the lack of a significant effect of (+)-PD-128,907 on seizure kindling to a GABA(A) receptor antagonist, pentylenetetrazol. Taken together and with literature findings, the data indicate that dopamine D(3) receptors function in the initiation of a dampening mechanism against the toxic effects of cocaine, a finding that might have relevance to psychiatric disorders of drug dependence, schizophrenia, and bipolar depression.
机译:先前的发现已证明多巴胺D(3)/ D(2)受体激动剂在急性给予可卡因的惊厥和致死作用中具有保护作用。此处提供的数据用于确定保护是通过D(3)链接的机制进行的,并且保护已扩展到癫痫发作。 D(3)拮抗剂SB-277011-A [4-喹啉甲酰胺,N- [反式-4- [2-(6-氰基-3,4-二氢-2(1H)-异喹啉基)et基]-环己基] -(9CI)]防止了D(3)/ D(2)受体激动剂(+)-PD-128,907 [(R-(+)-trans-3,4a,10b-四氢-4-丙基)的抗惊厥作用-2H,5H- [1]苯并吡喃并[4,3-b] -1,4-恶嗪-9-ol)]对可卡因诱发的癫痫发作。 D(3)/ D(2)激动剂(+)-PD-128,907提供的保护在D(3)受体缺陷型小鼠中被消除。在D(2)受体敲除小鼠中,(+)-PD-128,907的抗惊厥作用得以保留。 (+)-PD-128,907还通过每天重复使用60 mg / kg可卡因来预防可卡因点燃的癫痫发作的获得和表达。 (+)-PD-128,907还阻止了完全可卡因点燃的小鼠诱发的癫痫发作。尽管反复服用可卡因可卡因会增加癫痫发作和致死性的效力(降低的ED(50)值),但每天并用(+)-PD-128,907可以显着阻止这种效力的改变。在每天用可卡因和(+)-PD-128,907治疗的小鼠中,D(3)受体的密度(而非亲和力)增加。 (+)-PD-128,907对可卡因驱动的过程具有特异性,这是由于(+)-PD-128,907对GABA(A)受体拮抗剂戊四氮的癫痫发作缺乏显着影响所致。结合文献发现,数据表明多巴胺D(3)受体在针对可卡因毒性作用的抑制机制的启动中起作用,这一发现可能与药物依赖性,精神分裂症和双相抑郁症的精神疾病有关。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号